Partner David Rosen provides an overview of the Food and Drug Administration’s increasing use of consent decrees as compliance enforcement tools, stating that companies can potentially improve their manufacturing operations and systems quality by efficiently meeting the terms and conditions of a consent decree. He adds that entering into a consent decree requires significant time and resources, but notes that companies can better meet these requirements by proactively investing in a comprehensive quality program.
Click here to read the complete article.
Author(s)
Related Insights
July 10, 2025
Foley Viewpoints
One Big Beautiful Bill Act Permanently Increases the Lifetime Estate, Gift and GST Tax Exclusion
On July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act (OBBBA). The OBBBA extended and may permanent many key…
July 10, 2025
Foley Viewpoints
FTC's "Click-to-Cancel" Rule Invalidated
The Federal Appeals Court for the 8th Circuit invalidated the Federal Trade Commission's (FTC) “click-to-cancel” (aka “negative option”)…
July 10, 2025
Foley Viewpoints
Trump Administration Passes the One Big Beautiful Bill Act
On July 4, 2025, President Trump signed H.R. 1—referred to as the One Big Beautiful Bill Act (OBBBA). The OBBBA extends and makes…